【摘要】 目的探讨缬沙坦氢氯噻嗪治疗脑心综合征患者的临床效果。方法选取2016年1月～2019年1月我院收治的90例诊断为脑心综合征的患者作为研究对象,按照随机数字表法分为治疗组(45例)及对照组(45例),对照组采用一般治疗方法,治疗组采用一般治疗方法加用缬沙坦氢氯噻嗪方法。比较两组的临床疗效、心电图(ECG)改善、治疗前后C反应蛋白(CRP)、肿瘤坏死因子(TNF-α)及白介素-6(IL-6)水平。结果治疗组治疗后总有效率及ECG的总有效率高于对照组,治疗组的CRP、IL-6、TNF-α水平低于对照组,差异有统计学意义(P<0.05)。结论缬沙坦氢氯噻嗪能显著降低CRP,TNF-α及IL-6水平,可以提高脑心综合征患者的临床效果。更多还原

【Abstract】 Objective To investigate the clinical effect of Valsartan Hydrochlorothiazide in the treatment of patients with cerebral-cardiac syndrome. Methods A total of 90 cases of patients diagnosed with cerebral-cardiac syndrome admitted to our hospital from January 2016 to January 2019 were selected as the research objects, who were divided into treatment group(45 cases) and control group(45 cases) according to random number table method,the control group was treated by regular treatment, the treatment group was treated by regular treatment combined with Valsartan Hydrochlorothiazide. The clinical efficacy, electrocardiograph(ECG) improvement, C-reactive protein(CRP), tumor necrosis factor(TNF-α) and interleukin-6(IL-6) levels before and after treatment were compared between the two groups. Results The total effective rate and the ECG effective rate of the treatment group were higher than those of the control group,and the levels of CRP, IL-6 and TNF-α in the treatment group were lower than those of the control group, the differences were statistically significant(P<0.05). Conclusion Valsartan Hydrochlorothiazide can significantly reduce the CRP,TNF-α and IL-6 levels, which can improve the clinical curative effect of patients with cerebral-cardiac syndrome.更多还原